Type 1 diabetes mellitus following COVID-19 RNA-based vaccine.
J Diabetes Investig
; 13(7): 1290-1292, 2022 Jul.
Article
in English
| MEDLINE | ID: covidwho-1714218
ABSTRACT
The epidemic of coronavirus disease-2019 (COVID-19) is the major public health issue in the world. COVID-19 vaccines are one of the most effective strategies against COVID-19. Here we report a 36-year-old female patient who had thirst, polydipsia, polyuria, palpitations, loss of appetite, and fatigue 3 days after the first dose of COVID-19 RNA-based vaccines without a prior history of diabetes. Ten days after vaccination, she visited our hospital with diabetic ketoacidosis and was diagnosed with type 1 diabetes. Hyperglycemia (501 mg/dL), anion gap metabolic acidosis and ketonuria were observed. The glycated hemoglobin level was 7.0%. Islet-related autoantibodies were all negative. The glucagon tolerance test revealed attenuated secretion of insulin. Human leukocyte antigen was haplotype DRB1*0405-DQB1*0401, which was associated with type 1 diabetes in Japan. The present case suggests that COVID-19 RNA-based vaccines might trigger the onset of type 1 diabetes, even in subjects without prior histories of diabetes.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetic Ketoacidosis
/
Diabetes Mellitus, Type 1
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Case report
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Adult
/
Female
/
Humans
Language:
English
Journal:
J Diabetes Investig
Year:
2022
Document Type:
Article
Affiliation country:
Jdi.13781
Similar
MEDLINE
...
LILACS
LIS